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Basic Investigations 
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Objective: To investigate the effects of Aidi Injection (㡒䖾⊼ᇘ⎆ ADI) on the MicroRNAs (miRNA) expression 
profiles in human breast cancer cells and explore the potential targets of the cancer treatment.  
Methods: MCF-7 breast cancer cells were grown in RPMI 1640 medium supplemented with different 
concentrations of ADI. The inhibition of cell proliferation was measured by MTT assay. MCF-7 cells were treated 
by ADI with above 50% inhibiting concentration (IC50) for 48 h. The expression profiles of miRNA in ADI-treated 
and ADI-untreated MCF-7 cells were detected with miRNA microarray chips and the array data were verified by 
quantitative RT-PCR. MCF-7 cells were transiently transfected with miRNA mimics by liposome method. 
Potential mRNA targets were predicted by informatics analysis with TargetScan and PicTar software.  
Results: ADI significantly inhibited the proliferation of MCF-7 cells in a dose-dependent manner. The IC50 of ADI 
was 55.71 mg/mL after treatment for 48 h. The 60 mg/mL ADI was used as the therapeutic drug concentration. 
Microarray analysis identified 45 miRNAs that were up-regulated and 55 miRNAs that were down-regulated in 
response to ADI treatment. Many ADI-induced miRNAs were related to breast cancers. The microarray data were 
validated by qRT-PCR. Ectopic expression of 100 nmol/L mir-126 mimics significantly inhibited the proliferation 
of MCF-7 cells. The 12 potential target genes of mir-126 were predicted by both TargetScan and PicTar software.  
Conclusions: The miRNA may serve as therapeutic targets, and the modulation of miRNA expression is an 
important mechanism of ADI inhibiting breast cancer cell growth.  
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Chinese herbal medicine is widely used to treat cancer in 
China, with a certain effect1, and it has become one of 
main ways for cancer comprehensive treatment program. 
Strengthening the body resistance to eliminate 
pathogenic factors is a basic principle of Chinese herbal 
medicine for treatment of cancer.2,3 Aidi Injection (㡒䖾
⊼ᇘ⎆ ADI)  made by extraction of Ren Shen (Radix 
Ginsheng), Huang Qi (Radix Astragali), Ci Wu Jia 
(Radix Acantropanacis Senticosi), Ban Mao (Mylabri) is 
often used for clinical treatment of cancer.4,5 It is 
reported that ADI can inhibit growth of tumour and 
induce apoptosis, reverse multi-drug resistance, decrease 
the side-effect of radiotherapy or chemotherapy, increase 
immune function and improve life quality of the 
patient.6-9 The mechanisms of ADI anti-tumour activity 
have not, however, been completely defined. 
MicroRNAs (miRNAs) are a class of non-coding single 
chain small RNA molecules that function pos- 
ttranscriptional regulation of gene expression by binding 
to the 3’UTRs of their target mRNAs.10,11 In normal 
tissues, proper miRNA transcription, processing and 
binding to complementary sequences on the target 
mRNA result in the repression of target-gene expression 
through inhibition of protein translation or altering 
mRNA stability, so as to make cellular growth, 
proliferation, differentiation and cell death maintain at a 
normal level.12 Abnormal miRNA expression is related 
with various cancers, and these genes are thought to 
function as both tumour suppressors and oncogenes. 
Aberrant expression of miRNAs is involved in 
proliferation, infiltration, apoptosis and signal 
transduction pathways in breast cancer, and these small 
regulatory RNAs possibly serve as potential targets of 
anti-cancer drugs.13-17 Current report in Nature shows 
that the antiviral mechanism of interferon is through the 
modulation of cellular miRNAs, suggesting that 
miRNAs serve as targets for therapeutic intervention.18 
In this study, a microarray chip was used for miRNA 
expression profiling to test the hypothesis that ADI 
alters miRNA expression profiles, and it may clarify the 
antitumor effects of ADI.1 
METHODS 
Drugs and Reagents 
ADI (Each milliliter contained 300 mg raw drug. Batch  
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No. 20071217) was purchased from Guizhou Ebay 
Pharmaceutical Co. LTD (China); RPMI 1640 culture 
medium from Gibco Company; calf serum from PAA 
Company;  MTT from Genview Company; Trypsin from 
Amresco Company; Trizol reagent and DEPC from 
BioDev and Invitrogen Companies; TaqManR Micro- 
RNA kits from ABI Company; miR-RiboTM MicroRNA 
kits, mir-126 mimics, negative control mimics and 
fluorescence labelled siRNA from Guangzhou Ribobio 
Co., Ltd (China); HiPerFect transfection reagents from 
Qiangen company (Germany). 
Cell Culture 
Human breast cancer MCF-7 cells were purchased from 
the American Type Culture Collection (ATCC, USA) 
and cultured in RPMI 1640 medium (Gibco, USA) 
containing 10% heat-inactivated (56ć , 30 min) fetal 
calf serum, 2 mmol/L glutamine, penicillin (100 U/ml) 
and streptomycin (100 μg/mL), which was maintained in 
an incubator at 37ć  with 5% CO2 in a humidified 
atmosphere. The culture medium was replaced each 
three days and the cells at logarithmic growth phase 
were used for following experiments 
Intervention of ADI 
MCF-7 cells were seeded in 96-well culture plates at 
5×103 cells/well. After overnight incubation, the culture 
medium was replaced and added with final con- 
centrations of ADI, 20 mg/mL, 40 mg/mL, 60 mg/mL, 
80 mg/mL and 100 mg/mL, respectively, and a blank 
control group and a negative control group were set up 
with 4 duplicate wells in each group. After culture for 
48h, cell proliferation was measured with MTT assay. 
The experiment was replicated 3 times. The 50% 
inhibiting concentration (IC50) was calculated according 
to the effects of ADI inhibiting cell proliferation. MCF-7 
cells intervened with ADI of a concentration of over IC50 
for 48h were used for following Microarray assay. 
Detection of Cell Proliferation  
Cell viability was measured by the MTT assay 
(Genview). Cell proliferation was detected by the 
addition of 20 μl MTT (5 g/L) into each well at 37ć for 
4 h. After the culture medium was removed, DMSO 
(150 μL) was added and shaken with protecting from 
light to completely dissolve the formazan crystals. 
Absorbance (A) was measured at 490 nm with an ELISA 
plate reader (BioTek, Winooski, VT, USA). For each 
group, the experiment was repeated thrice with 4 
duplicate wells. The percentage of inhibition was 
calculated as follows: Inhibition rate (IR) = (1-ODSample / 
ODControl) × 100%. The IC50 value was determined by 
IC50 calculator according to the results of the MTT assay. 
RNA Extraction and Qualitative Detection 
Briefly, the cells were collected and washed with cold 
PBS buffer. Total RNA was isolated from 5×106 cells 
using Trizol according to the directions (Invitrogen). 
Absorbance (A) of the total RNA sample was measured 
by a spectrophotometer respectively at wavelengths of 
230, 260, and 280 nm to determine purification and 
concentration of the total RNA sample. Ratio of 28S  to 
18S in the total RNA sample was detected by 
electrophoresis on a 1% agarose gel containing 
formaldehyde to evaluate its purification and integrity. 
The RNA sample conforming to quality requirement was 
used for microarray assay. 
Microarray Assay of miRNA Expression Profiles 
Microarray assay was carried out by LC Sciences Bio-
tech Co. with a ȝParaflo™ microfluidic chip. 5 ȝg of 
total RNA sample was fractionated using a YM-100 
Microcon centrifugal filter (Millipore), attaining the 
isolated small RNAs  (<300 nt), which were 3’-extended 
with a poly (A) polymerase. An oligonucleotide tag was 
then ligated to the poly A. Hybridization was performed 
overnight on a ȝParaflo™ microfluidic chip using a 
micro-circulation pump (Atactic Technologies). On the 
microfluidic chip, each detection probe consisted of a 
chemically modified nucleotide coding segment 
complementary to target microRNA from the miRBase 
Sequence database version 10.0 (Sanger Institute, Cam-
bridge, U.K.; http://microrna.sanger.ac.uk/sequences). 
The detection probes were made by in situ synthesis 
using PGR (photogenerated reagent). Each probe 
sequence was repeated five times on the same array chip. 
The hybridization melting temperatures were balanced 
by chemical modifications of the detection probes. 
Hybridization was carried out with 100 ȝL 6 × SSPE 
buffer (0.90 mol/L NaCl, 60 mmol/L Na2HPO4, 6 
mmol/L EDTA, pH 6.8) containing 25% formamide at 
34ć. The specific fluorescence labelling with tag-
specific Cy3 and Cy5 dyes was used for hybridization 
detection. Hybridization images were collected using a 
laser scanner (GenePix 4000B, Molecular Device) and 
digitized using Array-Pro image analysis software 
(Media Cybernetics).  
Processing and Statistical Analysis of Microarray 
Data 
The data were analyzed after subtracting the background, 
the mean of duplicate points and the standard deviation 
were calculated and normalizing the signals using a 
LOWESS filters (Locally-weighted Regression). For 
bicolour labelling experiments, the ratio of the two 
detected signals (log2 transformed) and P-values of the t-
test were calculated. A P-value less than 0.05 was 
considered as statistically significant. Log2  with positive 
number expressed as up-regulation and
 
log2 with 
negative number 
 
as down-regulation. 
qRT-PCR for miRNA Analysis 
Real-time PCR-based quantification of miRNA was 
performed using miRNA analysis kits specific for each 
individual miRNA (Applied Biosystems) and Bulge-
LoopTM miRNA qPCR Primer Set (Guangzhou Ribobio 
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Co., Ltd, China) according to the instructions. 
Quantitative miRNA expression data were detected and 
analysed using a LightCycler 1.5 fluorescent qua- 
ntification  PCR instrument (Roche Applied Science). 
Transient miRNA Transfection 
MCF-7 cells at logarithmic growth phase were 
inoculated at 6×103 cells per well in 96-well plates with 
four duplicate wells in each group. For each transfection, 
MCF-7 cells were transfected with 100 nmol/L mir-126 
mimics, negative control mimics and fluorescently 
double labelled siRNA (Guangzhou RiboBio Co.,Ltd, 
China) with HiPerFect transfection reagent (Qiangen) 
following the instructions. The fluorescently labelled 
molecules were used for monitoring transfection of 
MCF-7 cells. After transfection for 48 h, cell viability 
was measured by the MTT assay. The transfection 
experiment was repeated thrice. 
Prediction of miRNA Target Genes 
The target genes of differential expression miRNAs 
were predicted by TargetScan and PicTar software follo-
wing the instructions in TargetScan (http://www.targets 
can.org) and PicTar (http://pictar.bio.nyu.edu).19, 20 
Statistical Analysis 
All the results were expressed as mean ̈́  standard 
deviation (SD). Statistical analysis was done with 
Studentϗs t-test for comparison of two groups. In all 
the test, differences with P<0.05 were considered 
statistically significant. 
RESULTS 
ADI Treatment Inhibited the Proliferation of MCF-7 
cells 
The MTT assay was used to determine the effects of 
ADI on MCF-7 human breast cancer cell growth. Figure 
1 illustrates the effects of 20-100 mg/mL ADI on the 
growth of MCF-7 cells after 48 h of incubation. After 48 
h of incubation, ADI inhibited the proliferation of MCF-
7 cells in a dose-dependent manner. While ADI con- 
centrations of 20-100 mg/m/, the cell numbers were 
reduced from 3 (±3) % to 93 (±7) %. The 50% inhibiting 
concentration (IC50) of ADI was 55.71 mg/mL after 
incubation for 48 h. The 60 mg/mL dose of ADI was 
used as the therapeutic concentration. 
ADI Treatment altered miRNA Expression Profiles 
in MCF-7 Cells 
To assess miRNAs response to ADI, microarray analysis 
of miRNA expression was conducted with miRNA-
enriched total RNAs extracted from human breast 
adenocarcinoma MCF-7 cells treated with 60 mg/mL 
ADI for 48 h. Compared with the control group, there 
were 100 differentially expressed miRNAs in the ADI 
treatment group. Among them, 45 miRNAs were up-
regulated and 55 miRNAs were down-regulated 
significantly (P<0.05), miRNAs down-regulated being 
more than up-regulated for ADI treatment. 
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Figure 1. ADI significantly inhibited the proliferation of MCF-7 cells. The results are expressed as cell percent survival 
relative to the control (mean±SD of three independent experiments) (*P<0.01) 
Verification of Differentially Expressed miRNAs by 
qRT-PCR 
To validate the microarray data, 5 miRNAs, mir-18a, 
mir-125b, mir-126, mir-181d and mir-195, were selected 
at random and their expression levels were assayed by 
qRT-PCR, and U6 was used for normalization. The 
results from the microarray and qRT-PCR were 
compared. The results showed that among the miRNAs 
selected for comparison, 4 miRNAs (mir-125b, mir-126, 
mir-181d and mir-195) were up-regulated whereas 1 
miRNAs (mir-18a) was down-regulated. The expression 
data obtained by qRT-PCR analysis are comparable to 
the microarray analysis data, although mir-195 was up-
regulated to a lesser degree in the qRT-PCR analyses 
(Figure 2). 
Mir-126 Repressed Proliferation of MCF-7 Cells  
In order to determine the effect of mir-126 on MCF-7 
cell proliferation activity, MCF-7 cells were transiently 
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transfected with 100 nmol/L mir-126 and negative 
control miRNA mimics. 48 h later, MCF-7 cell activities 
were detected with MTT and the effect of the mir-126 
was compared with that of the negative control mimics. 
It was found that mir-126 molecules could significantly 
inhibit the growth of the MCF-7 cell proliferation 
activity , with a cell survival rate of about 86% (Figure 
3).  
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Figure 2. Comparison of results of microarray and qRT-PCR. The fold changes refer to the expression fold changes of 
the selected miRNAs in ADI-treated cells compared with untreated control cells. The results are expressed as mean ± SD 
of three independent experiments (P<0.01). 
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Figure 3. Mir-126 inhibited the proliferation of MCF-7 cells. The breast caner cell line MCF-7 was transfected with mir-
126 mimics and negative control mimics (100 nmol/L). mir-126 could inhibit the cell growth (*P<0.01). Take negative 
control as 100%.
Predictions for the Target Genes of mir-126 
Mir-126 is down-regulated in breast cancer cell lines and 
it can repress cancer cell proliferation.21 In both 
microarray and qRT-PCR analyses, mir-126 was 
significantly up-regulated in MCF-7 cells after treatment 
with 60 mg/mL ADI for 48 h. This suggests that mir-126 
may play an important function in MCF-7 response to 
ADI. Thus, the two computational programs 
(TargetScan and PicTar) were employed to predict the 
targets of mir-126. In order to reduce sham positive rate, 
the genes commonly occurred in the two software were 
regarded as possible target genes. The 12 target genes 
predicted by the both programs are more likely to be the 
real targets of the miRNA, which were shown in Table 1.  
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Table 1. Potential target genes of mir-126 predicted by PicTar and TargetScan. 
Target 
gene 
RefSeq ID Target gene name Target 
gene 
RefSeq ID Target gene name 
IRS1 NM_005544 Insulin receptor substrate 1 FBXO33 NM_203301 F-box only protein 33 
PLK2 NM_006622 polo-like kinase 2 GOLPH3 NM_022130 Golgi phosphoprotein 3 
PHF15 NM_015288 PHD finger protein 15 SPRED1 NM_152594 Sprouty-related, EVH1 domain-
containing protein 1 
PTPN9 NM_002833 Tyrosine-protein phosphatase non-
receptor type 9 
CRK NM_005206 Proto-oncogene C-crk (P38) 
ITGA6 NM_000210 Integrin alpha-6 precursor (VLA-6) TOM1 NM_005488 Target of Myb protein 1 
RGS3 NM_017790 Regulator of G-protein signaling 3 SLC7A5 NM_003486 Large neutral amino acids 
transporter small subunit 1 
 
DISCUSSION 
Cancer is a class of diseases, characterized by cell 
uncontrolled growth, infiltration, and sometimes 
metastasis, which are caused by inactivation of tumour 
suppressor genes and abnormal expression of oncogenes. 
Previously, it was held that protein-coding oncogenes 
and tumour suppressor genes were causes of tumour 
generation. With the discovery of non-protein-coding 
RNA, the traditional concept is being challenged. It is 
increasingly recognized that miRNAs, members of non-
protein-coding RNAs, play important roles in formation 
of cancer .  
miRNAs are important regulators of gene expression, 
and they show effects of tumour suppressor genes and 
abnormal expression of oncogenes through regulating the 
expression of downstream target genes, including 
transcription factors, oncogenes, and tumour suppressor 
genes.22,23 Thus, the miRNA with oncogenic or tumour 
suppressive action may be used as a therapeutic target to 
control cancers.17 Previous studies on molecular 
pharmacology of TCM for treatment of breast cancer 
have much focused on the alterations of expression of 
tumour-related protein-coding genes.24-26 However, very 
few studies were involved in non-coding miRNA with 
function of regulating gene expressions. Chinese herbal 
medicine has definite therapeutic effects on cancer, so, 
the explanation of the anti-cancer effect by regulating 
miRNA and the mediating molecular pathway will 
provide a new research thinking and theoretical basis for 
cancer treatment with Chinese herbal medicine. 
ADI is an injection of Chinese herbal medicine with 
multi-components, which is prepared by the extract of 
Ren Shen (Radix Ginsheng), Huang Qi (Radix Astragali), 
Ci Wu Jia (Radix Acantropanacis Senticosi) and Ban 
Mao (Mylabri), with unclear mechanisms. Since it is 
difficult to evaluate the effects of Chinese herbal 
medicine with multi-components, in the study the anti-
cancer mechanism of ADI was investigated through a 
holistic evaluation of miRNA expressions, so as to 
explore potential treated targets of ADI. 9 
The results in the study indicated that the expressions of 
100 miRNAs in MCF-7 cells were regulated by ADI. 
Through literature search, it was found that the ADI-
regulated miRNAs in this study had been reported by the 
previous studies.13-16, 27-31 Many breast cancer-related 
miRNAs were significantly affected by ADI exposure. 
For example, the expressions of mir-27a, mir-181b, mir-
191, and mir-210 were up-regulated in human breast 
cancer,
 27,28
 but they were significantly down-regulated 
by ADI. mir-155 with an oncogenic role was up-
regulated in human breast cancer,27,29 but it was 
significantly down-regulated by ADI in this study. The 
expressions of miRNA let-7, mir-125b, mir-126 and mir-
7 were down-regulated in human breast cancer with 
cancer suppressor gene action.27, 30 let-7 miRNAs were 
down-regulated in the breast cancer patient with either 
lymph node metastasis or higher proliferation index.27 It 
has been proved that the RAS, HMGA2 and MYC 
oncogenes are 3 target genes of the let-7 miRNAs,32-34 
which influence proliferation of cancer cells through 
regulating target genes. mir-126 is identified as 
metastasis suppressor microRNA in human breast 
cancer
35
 and it  regulates expression of  target gene IRS-
1 to inhibit proliferation of cancer cells.21 mir-7 is  a 
suppressor microRNA in human breast cancer30 and it 
targets Pak130 and EGFR36 to produce cancer-inhibiting 
action. The potential tumour suppressor mir-125b targets 
oncogenes ERBB2 and ERBB3 in breast cancer cells.37 
In this study, expressions of let-7RMA, mir-126, mir-7 
and mir-125b, etc. were significantly up-regulated by 
ADI. Thus, ADI-induced miRNAs display an anti-
tumour activity for breast cancer.  
It may be expected that targets of miRNAs up-regulated 
by ADI possibly are oncogenes or genes encoding 
proteins with potential oncogenic functions. It was 
reported that mir-126 was down-regulated in breast 
cancer cell lines.21 mir-126 was up-regulated by ADI and 
it had potential roles as a tumour-suppressor gene in 
tumour genesis. It is showed that cancer-associated genes 
were potentially regulated by mir-126. Therefore, mir-
126 was selected for preliminary bio-informatics analysis 
and it was found that its targets included the IRS1, 
SLC7A5 and CRK genes. However, the regulated precise 
target genes remain to be further confirmed.  
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In brief, miRNA is a key component in genes regulating 
networks and it has functions of tumour suppressor genes 
or oncogenes in breast cancer genesis. Most related 
researches have showed that miRNAs are associated with 
breast cancer and can serve as the potential targets for 
cancer treatment. In this study, it was found that ADI 
altered the expression profiles of miRNAs in human 
breast cancer cells when ADI treatment effectively 
inhibited the proliferation of MCF-7 cells. Informatics 
analysis showed that cancer-associated genes were 
potentially regulated by mir-126. This suggests that 
regulation of ADI on miRNAs and the molecular 
pathway possibly is one of main mechanisms for 
treatment of breast cancer.  
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